RESUMO
INTRODUCTION: Available studies have shown the involvement of nitric oxide (NO) in the processes that lead to neurodegeneration in Parkinson's disease (PD). Also, the use of inhibitors of the inducible isoform of NO-synthase (iNOS) promotes neuroprotection and attenuates dopamine (DA) loss in experimental models of Parkinsonism. In addition, NO also appears to be involved in cardiovascular changes in 6-hydroxydopamine (6-OHDA)-induced Parkinsonism. The current study aimed to evaluate the effects of iNOS inhibition on cardiovascular and autonomic function in animals that were subjected to Parkinsonism by the administration of 6-OHDA. MATERIALS AND METHODS: The animals underwent stereotaxic surgery for bilateral microinfusion of the neurotoxin 6-OHDA (6 mg/mL in 0.2% ascorbic acid in sterile saline solution) or vehicle solution for the Sham group. From the day of stereotaxis until the day of femoral artery catheterization, the animals were treated with the iNOS inhibitor, S-methylisothiourea (SMT; 10 mg/kg; i. p.) or saline solution (0.9%; i. p.) for 7 days. The animals were divided into four groups: Sham-Saline, Sham-SMT, 6-OHDA-Saline, and 6-OHDA-SMT. Subsequent analyses were performed on these four groups. After 6 days, they underwent catheterization of the femoral artery, and 24 h later, mean arterial pressure (MAP) and heart rate (HR) were recorded. Another group of animals (the 6-OHDA and Sham groups) was assessed for aortic vascular reactivity after 7 days of bilateral infusion of 6-OHDA or vehicle, in which cumulative concentration-effect curves (CCEC) were made for phenylephrine (Phenyl), acetylcholine and sodium nitroprusside (NPS). Also, CCEC in the presence of Nw-nitro-arginine-methyl-ester (l-NAME) (10-5 M), SMT (10-6 M), and indomethacin (10-5 M) blockers were made. RESULTS: The effectiveness of the 6-OHDA lesion was confirmed with the reduction of DA in 6-OHDA animals. However, treatment with SMT could not reverse the loss of DA. Concerning the baseline parameters, SBP and MAP values were lower in 6-OHDA animals compared to their Sham control, with no effect of treatment with SMT. In the analysis of SBP variability, a decrease in variance, the VLFabs component, and the LFabs component were observed in the 6-OHDA groups when compared to their controls, regardless of treatment with SMT. It was also observed that intravenous injections of SMT resulted in an increase in BP and a decrease in HR. However, the response was not different between the Sham and 6-OHDA groups. In vascular function, there was a hyporeactivity to Phenyl in the 6-OHDA group, and when investigating the mechanisms of this hyporeactivity, it was seen that the Rmax to Phenyl increased with incubation with SMT, indicating that iNOS could be involved in the vascular hyporeactivity of animals with Parkinsonism. CONCLUSION: Thus, the set of results presented in this study suggests that part of the cardiovascular dysfunction in animals subjected to 6-OHDA Parkinsonism may be peripheral and involve the participation of endothelial iNOS.
Assuntos
Sistema Cardiovascular , Transtornos Parkinsonianos , Animais , Masculino , Ratos , Dopamina , Inibidores Enzimáticos/farmacologia , NG-Nitroarginina Metil Éster/farmacologia , Oxidopamina/farmacologia , Transtornos Parkinsonianos/induzido quimicamente , Transtornos Parkinsonianos/tratamento farmacológico , Fenilefrina , Ratos Wistar , Solução SalinaRESUMO
The current investigation compared intranigral lipopolysaccharide (LPS), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 6-hydroxydopamine (6-OHDA) administrations, in the light of neurochemical, behavioral and endogenous antioxidant glutathione alterations. All the results were collected 1, 3 and 7 days after the lesions. LPS produced a delayed reduction of striatal dopamine, whereas homovanillic acid was drastically increased at the first time-point. Comparatively, MPTP promoted dopamine reduction 3 and 7 days with increase of homovanillic acid. Whilst, 6-OHDA generated initial increase of dopamine and homovanillic acid followed by subsequent decrease of this neurotransmitter accompanied by reductions of dopamine metabolites at the same periods. Furthermore, nigral glutathione demonstrated to be a far more sensitive target for LPS than for MPTP or 6-OHDA. Behavioral data indicated impairments induced by MPTP, 6-OHDA but not LPS. In conclusion, it is suggested that intranigral LPS can provide new insights about neuroinflammation, simulating features of the pre-motor phase of Parkinson's disease.
Assuntos
1-Metil-4-Fenil-1,2,3,6-Tetra-Hidropiridina , Comportamento Animal/efeitos dos fármacos , Dopamina/metabolismo , Glutationa/metabolismo , Lipopolissacarídeos/farmacologia , Oxidopamina , Doença de Parkinson/metabolismo , Animais , Corpo Estriado/efeitos dos fármacos , Corpo Estriado/metabolismo , Modelos Animais de Doenças , Masculino , Doença de Parkinson/etiologia , Doença de Parkinson/psicologia , Ratos , Ratos Wistar , Substância Negra , Fatores de TempoRESUMO
AIM: Parkinson's disease (PD) is a progressive neurodegenerative disease that manifests itself clinically after reaching an advanced pathological stage. Besides motor signals, PD patients present cardiovascular and autonomic alterations. Recent data showed that rats induced to Parkinsonism by 6-hydroxydopamine (6-OHDA) administration in the substantia nigra pars compacta (SNpc) showed lower mean arterial pressure (MAP) and heart rate (HR), as reduction in sympathetic modulation. The paraventricular nucleus of the hypothalamus (PVN) is an important site for autonomic and cardiovascular control, and amino acid neurotransmission has a central role. We evaluate PVN amino acid neurotransmission in cardiovascular and autonomic effects of 6-OHDA Parkinsonism. METHODS: Male Wistar rats were submitted to guide cannulas implantation into the PVN. 6-OHDA or sterile saline (sham) was administered bilaterally in the SNpc. After 7 days, cardiovascular recordings in conscious state was performed. RESULTS: Bicuculline promoted an increase in MAP and HR in sham group and exacerbated those effects in 6-OHDA group. NBQX (non-NMDA inhibitor) did not promote changes in sham as in 6-OHDA group. On the other hand, PVN microinjection of LY235959 (NMDA inhibitor) in sham group did not induced cardiovascular alterations, but decreased MAP and HR in 6-OHDA group. Compared to Sham group, 6-OHDA lesion increased the number of neuronal nitric oxide synthase (nNOS)-immunoreactive neurons in the PVN and, nNOS inhibition promoted higher increases in MAP and HR. CONCLUSION: Our data suggest that the decreased baseline blood pressure and heart rate in animals with Parkinsonism may be due to an increased GABAergic tone via nNOS in the PVN.
Assuntos
Ácido Glutâmico/metabolismo , Óxido Nítrico Sintase Tipo I/metabolismo , Núcleo Hipotalâmico Paraventricular/metabolismo , Ácido gama-Aminobutírico/metabolismo , Animais , Pressão Sanguínea/fisiologia , Sistema Cardiovascular/metabolismo , Frequência Cardíaca/fisiologia , Masculino , Doenças Neurodegenerativas/metabolismo , Transtornos Parkinsonianos/induzido quimicamente , Transtornos Parkinsonianos/metabolismo , Ratos WistarRESUMO
Parkinson's disease (PD) is mainly characterized by motor signals. However, non-motor signals also affect and decrease the quality of life of PD patients. Among these non-motor signs are cardiovascular disorders as orthostatic hypotension, postprandial hypotension and cardiac arrhythmias, which may be due to the involvement of both central nervous system and peripheral autonomic nervous system. In the present study we investigated the cardiovascular function, evaluating cardiovascular reflexes (chemoreflex and baroreflex), in an animal model of Parkinsonism induced by bilateral infusion of the toxin 6-hydroxydopamine (6-OHDA), in the substantia nigra pars compacta (SNpc). The results showed that the animals induced to Parkinsonism had lower arterial pressure (AP) and heart rate HR) compared to control animals. We showed that after activation of the baroreceptors by phenylephrine (Phe) and sodium nitroprusside (SNP), the baroreflex sensitivity index was not changed between the groups. However, there was a greater increase in the AP when stimulated with Phe and greater tachycardia when stimulated with SNP in 6-OHDA animals. After activation of the peripheral chemoreceptors through KCN injection (cytotoxic hypoxia), there was a higher increase in pressor and bradycardic response in injured animals with bilateral 6-OHDA. These changes in the cardiovascular reflexes may be important adjustments mechanisms to maintain the cerebral blood flow in those animals, and may be a result of denervation supersensitivity to catecholamines in autonomic targets.
Assuntos
Barorreflexo , Células Quimiorreceptoras/fisiologia , Oxidopamina , Transtornos Parkinsonianos/fisiopatologia , Animais , Pressão Sanguínea , Células Quimiorreceptoras/efeitos dos fármacos , Frequência Cardíaca , Masculino , Nitroprussiato/farmacologia , Transtornos Parkinsonianos/induzido quimicamente , Fenilefrina/farmacologia , Ratos Wistar , Substância Negra/efeitos dos fármacos , Substância Negra/fisiopatologiaRESUMO
BACKGROUND: Rotenone exposure in rodents provides an interesting model for studying mechanisms of toxin-induced dopaminergic neuronal injury. However, several aspects remain unclear regarding the effects and the accuracy of rotenone as an animal model of Parkinson's disease (PD). In this study, we investigated the motor and depressive-like behaviors associated to neurochemical alterations induced by a novel protocol of rotenone administration. METHODS: In the first experiment, we adopted the paw test to characterize an effective dose of rotenone able to promote nigrostriatal toxicity. In the second experiment, control and rotenone 2.5 mg/kg groups were injected (ip) for 10 consecutive days. RESULTS: This test indicated that intraperitonial (ip) rotenone at 2.5 and 5.0 mg/kg promoted a significant neurotoxicity to striatum and nucleus accumbens. However, only 2.5 mg/kg of rotenone was associated to a negligible mortality rate. Open-field tests were conducted on 1, 7, 14 and 21 day after the last day of treatment and showed an important locomotor impairment, confined to 1 and 7 day. Besides, rotenone affected dopamine levels and increased its turnover in the striatum. Modified forced swim test (performed on 22 day) and sucrose preference test (performed on 14 and 21 day) demonstrated that rotenone produced impairments in the swimming and immobility. In parallel, increments in the serotonin and noradrenaline turnovers were observed in the striatum and hippocampus of the rotenone group. CONCLUSIONS: These data suggest important participations of serotonin and noradrenaline in depressive-like behaviors induced by rotenone. Thus, it is proposed that the current rotenone protocol provides an improvement regarding the existing rotenonemodels of PD.
Assuntos
Química Encefálica/efeitos dos fármacos , Depressão/induzido quimicamente , Atividade Motora/efeitos dos fármacos , Rotenona/toxicidade , Animais , Dopamina/análise , Dopamina/metabolismo , Masculino , Norepinefrina/análise , Norepinefrina/metabolismo , Doença de Parkinson Secundária/induzido quimicamente , Ratos , Ratos Wistar , Serotonina/análise , Serotonina/metabolismoRESUMO
Rotenone exposure in rodents provides an interesting model for studying mechanisms of toxin-induced dopaminergic neuronal injury. However, several aspects remain unclear regarding the effects and the accuracy of rotenone as an animal model of Parkinson's disease (PD). In order to counteract these limitations, this study characterized a precise neurotoxin-delivery strategy employing the bilateral intranigral administration protocol of rotenone as a reliable model of PD. We performed bilateral intranigral injections of rotenone (12 µg) and subsequent general activity (1, 10, 20, and 30 days after rotenone) and cognitive (7, 8, 15, and 30 days after rotenone) evaluations followed by neurochemical and immunohistochemical tests. We have observed that rotenone was able to produce a remarkable reduction on the percentage of tyrosine hydroxylase immunoreactive neurons (about 60%) within the substantia nigra pars compacta. Dopamine (DA) was severely depleted at 30 days after rotenone administration, similarly to its metabolites. In addition, an increase in DA turnover was detected at the same time-point. In parallel, striatal serotonin and its metabolite were found to be increased 30 days after the neurotoxic insult, without apparent modification in the serotonin turnover. Besides, motor behavior was impaired, mainly 1 day after rotenone. Furthermore, learning and memory processes were severely disrupted in different time-points, particularly at the training and test session (30 days). We now provide further evidence of a time-dependent neurodegeneration associated to cognitive impairment after the single bilateral intranigral administration of rotenone. Thus, it is proposed that the current rotenone protocol provides an improvement regarding the existing rotenone models of PD.
Assuntos
Degeneração Neural/induzido quimicamente , Transtornos Parkinsonianos/induzido quimicamente , Rotenona/toxicidade , Substância Negra/efeitos dos fármacos , Desacopladores/toxicidade , Animais , Aprendizagem da Esquiva/efeitos dos fármacos , Modelos Animais de Doenças , Neurônios Dopaminérgicos/efeitos dos fármacos , Neurônios Dopaminérgicos/metabolismo , Neurônios Dopaminérgicos/patologia , Comportamento Exploratório/efeitos dos fármacos , Ácido Hidroxi-Indolacético/metabolismo , Masculino , Microinjeções/métodos , Atividade Motora/efeitos dos fármacos , Degeneração Neural/patologia , Degeneração Neural/fisiopatologia , Transtornos Parkinsonianos/patologia , Transtornos Parkinsonianos/fisiopatologia , Ratos , Ratos Wistar , Neurônios Serotoninérgicos/efeitos dos fármacos , Neurônios Serotoninérgicos/metabolismo , Neurônios Serotoninérgicos/patologia , Serotonina/metabolismo , Substância Negra/metabolismo , Substância Negra/patologia , Tirosina 3-Mono-Oxigenase/metabolismoRESUMO
The present study investigated the neurochemical, motor and cognitive effects of pioglitazone in a rat model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). In the first experiment, we administered MPTP, and 1h later administered a single oral dose of pioglitazone (5, 15 and 30 mg/kg). The following day, we performed the open-field test and neurochemical dose response curve. We demonstrated that 30 mg/kg of pioglitazone was capable of restoring striatal dopamine (DA) concentrations and motor behaviors. A second experiment was conducted to test the effects of two protocols (acute and chronic) of pioglitazone (30 mg/kg) administration in the open-field test, two-way active avoidance task and in the DA and metabolites levels. The acute protocol consisted of a single oral administration 1 h after MPTP, whereas the chronic protocol was performed with daily administrations starting 1 h after MPTP and ending 22 days after that. Results showed that neither protocol was able to reverse the cognitive impairment promoted by MPTP. We also demonstrated that acute treatment generated some level of neuroprotection, as confirmed by the absence of DA reduction in the group treated with pioglitazone in comparison to the sham group. By contrast, chronic treatment leaded to a reduction of striatal DA, close to MPTP administration alone. These findings suggest that acute administration of pioglitazone (30 mg/kg) was more efficient in generating beneficial effects on motor behaviors and in striatal DA levels. Nevertheless, we failed to demonstrate that pioglitazone administration improved performance on a dopamine-related cognitive task after MPTP.
Assuntos
Corpo Estriado/efeitos dos fármacos , Dopamina/metabolismo , Intoxicação por MPTP/tratamento farmacológico , Atividade Motora/efeitos dos fármacos , Tiazolidinedionas/administração & dosagem , Análise de Variância , Animais , Corpo Estriado/metabolismo , Relação Dose-Resposta a Droga , Intoxicação por MPTP/metabolismo , Masculino , Atividade Motora/fisiologia , Pioglitazona , Distribuição Aleatória , Ratos , Ratos Wistar , Tiazolidinedionas/uso terapêuticoRESUMO
Devido aos efeitos terapêuticos, o ultra-som tem se tornado ferramenta indispensável no tratamento fisioterapêutico de alterações causadas por lesões e em diversas doenças, porém seu uso em pacientes pediátricos é controverso por possíveis distúrbios e danos à placa epifisária. O objetivo deste estudo é verificar se o ultra-som contínuo apresenta efeitos de alteração na placa de crescimento da tíbia de coelhas. Oito coelhas da raça Nova Zelândia com dois meses de idade foram submetidas a um tratamento usando ultra-som terapêutico de forma contínua com dose de 1W/cm² na região lateral da articulação do joelho direito por 5min, durante 10 dias com dois dias de intervalo após a 5ª aplicação. A articulação do joelho esquerdo foi utilizada como controle. A análise histológica mostrou uma alteração na espessura da cartilagem epifisária, sendo que no lado tratado o tamanho foi 24,40 por cento maior do que no controle (p < 0,0001), enquanto a análise radiológica não apresentou diferença entre os membros. Conclui-se que o ultra-som terapêutico na forma utilizada produz alterações histológicas significativas na espessura da cartilagem no lado tratado, sugerindo uma aceleração no metabolismo da placa.
The therapeutic efficiency of ultrasound has become an indispensable tool of physical therapy treatment in cases of alteration by lesions and in many kinds of sickness. However, in pediatric cases the use of ultrasound is controversial due to possible disturbance and damage to the growth plate. The aim of this study is to find out if the continuous ultrasound presents alteration effects on the growth plate of female rabbits. Eight New Zealand female rabbits with two months of age were tested. They were treated by continuous therapeutic ultrasound with doses of 1 W/cm² in the lateral region of the right knee joint for five minutes, during 10 days, with an interval of two days after five applications. The left knee joint was used as a control. The histological analysis showed an alteration in the thickness of the growth plate on the treated side 24.40 percent bigger than in the left knee joint of the control (p < 0.0001). On other hand, the radiological analysis did not show any difference between the limbs. The conclusion was that the therapeutic ultrasound produced significant histological alterations in the cartilage thickness on the treated side according to the manner it was used in the experiment. Such fact suggests an acceleration in the growth plate metabolism.
Debido a los efectos terapéuticos, la ultrasonografía se ha convertido en una herramienta indispensable al tratamiento fisioterapéutico de las alteraciones causadas por lesiones y en diversas enfermedades, a pesar de esto su uso en pacientes pediátricos es controversial por los posibles disturbios y daños a la placa epifisaria. El objetivo de este estudio es verificar si la ultrasonografía continua presenta efectos de alteración en la placa de crecimiento de al tibia de conejas. Ocho conejas de la raza Nueva Zelanda con 2 meses de edad fueron sometidas a un tratamiento usando ultrasonografía terapéutica de forma continua con dosis de 1W/cm² en la región lateral de la articulación de la rodilla derecha por 5 min, durante 10 días con 2 días de intervalo después de la 5ª aplicación. La articulación de la rodilla izquierda fue utilizada como control. El análisis histológico reportó una alteración en la espesura del cartílago epifisario, en el lado tratado el tamaño fue de 24,40 por ciento mayor del que en el control (p < 0,0001); mientras que el análisis radiológico no presentó ninguna diferencia entre los miembros. Por tanto, se concluye que la ultrasonografía terapéutica en la forma utilizada produce alteraciones histológicas significativas en la espesura del cartílago en el lado tratado, lo que sugiere una aceleración en el metabolismo de la placa.